Research programme: nitroxyl-based cardiovascular therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: nitroxyl-based cardiovascular therapeutics - Bristol-Myers Squibb

Alternative Names: CXL-1036; HNO donors - Bristol-Myers Squibb; HNO prodrugs - Bristol-Myers Squibb; nitroxyl donors - Bristol-Myers Squibb

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Nitrogen oxides; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic heart failure; Pulmonary arterial hypertension

Most Recent Events

  • 08 Dec 2015 Cardioxyl Pharmaceuticals has been acquired and merged into Bristol-Myers Squibb
  • 20 Nov 2014 Preclinical pharmacodynamics data in Chronic heart failure presented at the 87th Annual Scientific Sessions of the American Heart Association (AHA-2014)
  • 16 Sep 2014 Preclinical trials in Chronic heart failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top